---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-082875"
form_type: "8-K"
ticker: "ANRO"
cik: "0001999480"
company_name: "Alto Neuroscience, Inc."
filed_at: "2026-07-13T11:39:07+00:00"
generated_at: "2026-07-13T11:40:04.748609+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Alto Neuroscience reports ~$244.2M cash; plans additional Phase 3 trial for ALTO-207

## Summary
- Preliminary cash, cash equivalents and restricted cash of ~$244.2M as of June 30, 2026 (unaudited).
- Company intends to accelerate ALTO-207 development, including an additional Phase 3 monotherapy trial for treatment-resistant depression.
- No other financial results or guidance provided in this filing.

## SEC filing metadata
- accession: 0001104659-26-082875
- form_type: 8-K
- ticker: ANRO
- cik: 0001999480
- company_name: Alto Neuroscience, Inc.
- filed_at: 2026-07-13T11:39:07+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1999480/000110465926082875/0001104659-26-082875-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1999480/000110465926082875/tm2620297d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-082875
- JSON: https://secwatch.observer/filing/0001104659-26-082875.json
- Plain text: https://secwatch.observer/filing/0001104659-26-082875.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.